白细胞介素-17A与雌激素受体α和β在上皮性卵巢癌组织中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2024.01.007

Abstract

Abstract: OBJECTIVE: To investigate expression levels of interleukin(IL)-17A and estrogen receptor α(ERα) and ERβ in epithelial ovarian cancer(EOC) tissues and their relationship with clinicopathological features and prognosis. METHODS: Clinical and pathological data of 102 EOC patients admitted to Wuxi Maternal and Child Health Hospital during August 2018-August 2022 were retrospectively analyzed. IL-17A, ERα, and ERβ mRNA expressions in cancer tissues and paracellular tissues were detected by real-time fluorescence quantitative PCR(qPCR), and the ERα/β ratio was calculated. The relationships between IL-17A m RNA, ERα/β and clinicopathological features were analyzed. Effects of IL-17A m RNA, ERα/β on the prognostic overall survival of EOC were analyzed by the Kaplan-Meier method and Cox regression analysis.RESULTS: Expressions of IL-17A, ERα and ERα/β were higher in the cancer than the paracancer tissues, while the expression of ERβ was decreased(P<0.05). The high and low expression groups of IL-17A and ERα/βwere divided by the mean values of 0.52 and 3.85, respectively, and the results showed that high IL-17A expression and high ERα/β ratio were associated with FIGO stage, lymph node metastasis, and the amount of ascites(P<0.05). The follow-up period ranged from 12 to 60 months, with a median follow-up period of 36 months, and a total of 38 cases(37.25%) died during the follow-up period. Kaplan Meier analysis showed that the cumulative survival rate of those with high IL-17A mRNA expression was lower than that of those with low expression(P<0.05), and the cumulative survival rate of those with high ERα/β ratio was lower than that of those with low ERα/β ratio(P<0.05). Multifactorial Cox analysis showed that FIGO stage III + IV, postoperative residual foci >2 cm, high expression of IL-17A mRNA, and high ERα/β ratio were independent risk factors for overall survival in patients with EOC(P<0.05). CONCLUSION: IL-17A, ERα and ERα/βwere up-regulated while the ERβ mRNA level was down-regulated in EOC, and the prognosis of EOC patients with high IL-17A expression and high ERα/β ratio was poor.

Key words: epithelial ovarian cancer, interleukin-17A, estrogen receptor α, estrogen receptor β, clinicopathological features, prognosis

CLC Number:

R737.31

WANG Kefang, CHEN Yu, WU Chenyu, LIU Mei, WANG Lijie, TIAN Jianguang, ZHOU Xiaohui, XU Lan. Clinicopathological roles of IL-17A and estrogen receptors α, β in epithelial ovarian cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 42-47.

References

[1] ARMSTRONG D K, ALVAREZ R D, BAKKUM-GAMEZ J N,et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(2):191-226.
[2] 黄海涛,陈姝玉,耿旭,等. 2005—2016年中国女性卵巢癌发病及死亡趋势研究[J].中国全科医学, 2022, 25(8):990-994.
[3] XU X L, HUANG Z Y, YU K, et al. Estrogen biosynthesis and signal transduction in ovarian disease[J]. Front Endocrinol:Lausanne, 2022, 13:827032.
[4] NEGI A, KESARI K K, VOISIN-CHIRET A S. Estrogen receptor-α targeting:PROTACs, SNIPERs, peptide-PROTACs,antibody conjugated PROTACs and SNIPERs[J]. Pharmaceutics,2022, 14(11):2523.
[5] LIU M M, ZHANG Y N, XU Q Q, et al. Apigenin inhibits the histamine-induced proliferation of ovarian cancer cells by downregulating ERα/ERβ expression[J]. Front Oncol, 2021,11:682917.
[6] CHENG R, XUE X O, LIU X L. Expression of IL17A in endometrial carcinoma and effects of IL17A on biological behaviour in Ishikawa cells[J]. J Int Med Res, 2020, 48(9):300060520950563.
[7] 朱熠,张国楠.卵巢癌、输卵管癌和腹膜癌FIGO2013分期和临床意义的解读[J].肿瘤预防与治疗, 2015, 28(5):291-294.
[8] SCHOUTROP E, MOYANO-GALCERAN L, LHEUREUX S,et al. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment[J]. Semin Cancer Biol, 2022, 86(Pt 3):207-223.
[9] BANERJEE A, CAI S R, XIE G Z, et al. A novel estrogen receptor β agonist diminishes ovarian cancer stem cells via suppressing the epithelial-to-mesenchymal transition[J].Cancers, 2022, 14(9):2311.
[10] WU H M, ZENG L H, OU J X, et al. Estrogen acts through estrogen receptor-β to promote mannan-induced psoriasis-like skin inflammation[J]. Front Immunol, 2022, 13:818173.
[11] YU C Y, NIU X L, DU Y R, et al. Correction to:IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/p-STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment[J]. Cancer Immunol Immunother, 2023, 72(8):2875-2877.
[12] GUO N, ZHANG J W. Interleukin-17 promotes the development of ovarian cancer through upregulation of MTA1expression[J]. Am J Cancer Res, 2022, 12(12):5646-5656.
[13] 刘长慧,金百灵.宫颈癌合并阴道炎患者病原菌感染情况及Th17细胞和血清细胞因子的变化[J].中国病原生物学杂志,2021, 16(7):837-840.
[14] POPOVIĆ M, DEDIĆ PLAVETIĆ N, VRBANEC D, et al.Interleukin 17 in early invasive breast cancer[J]. Front Oncol,2023, 13:1171254.
[15] KANG S P, WU Q L, YANG B Y, et al. Estrogen enhanced the expression of IL-17 by tissue-resident memory γδT cells from uterus via interferon regulatory factor 4[J]. FASEB J, 2022, 36(2):e22166.
[16] SHUAI C, YANG X M, PAN H M, et al. Estrogen receptor downregulates expression of PD-1/PD-L1 and infiltration of CD8+T cells by inhibiting IL-17 signaling transduction in breast cancer[J]. Front Oncol, 2020, 10:582863.
[17] ALI E T, MASRI M A M, SIDDIG E E, et al.Immunohistochemical expression of interleukin-17 and hormonal receptors in benign and malignant breast lesions[J]. BMC Res Notes, 2020, 13(1):300.
[18] SPAŁKOWSKA M, DYDUCH G, BRONIATOWSKA E, et al.Molecular proof of a clinical concept:expression of estrogen alpha-, beta-receptors and G protein-coupled estrogen receptor 1(GPER)in histologically assessed common nevi,dysplastic nevi and melanomas[J]. Medicina, 2021, 57(11):1228.
[19] MA Y F, CHEN C, LI D Q, et al. Targeting of interleukin(IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer[J]. Oncotarget, 2017, 8(5):7614-7624.
[20] TSAI Y F, HUANG C C, LIN Y S, et al. Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis[J]. Cancer Immunol Immunother,2021, 70(8):2339-2351.
[21] LI S, NA R S, LI X H, et al. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(4):188758.
[22] TAKANO E A, YOUNES M M, MEEHAN K, et al. Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival[J]. BMC Cancer, 2023, 23(1):459.
[23] CASTELLANOS M R, FANOUS E, THAKER R, et al.Expression patterns and clinical significance of estrogen receptor in non-small cell lung cancer[J]. Pathol Res Pract,2023, 241:154298.
[24] KUMAR V, CHAUHAN S S. Daidzein induces intrinsic pathway of apoptosis along with ER α/β ratio alteration and ROS production[J]. Asian Pac J Cancer Prev, 2021, 22(2):603-610.
[25] CHAKRABORTY B, BYEMERWA J, KREBS T, et al.Estrogen receptor signaling in the immune system[J]. Endocr Rev, 2023, 44(1):117-141.

Clinicopathological roles of IL-17A and estrogen receptors α, β in epithelial ovarian cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XUE Song, HU Jiahai, DONG Xiangning. Expression of PGAM5 and its association with clinicopathologic characteristics in pancreatic cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 29-34.
[2]	ZHU Wenbiao, QIU bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 426-430.
[3]	YANG Shangying, HUANG Mingxiang, XU Dexin, LIU Jiafu, CHEN Xinfu. Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 467-472.
[4]	GUO Wenjing, DENG Hui, SONG Ping, ZHANG Mengxian. Expression and biological functions of TGFBI in glioma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 341-348.
[5]	WEI Laifeng, HONG Chaoqun, CHEN Liuyi, XU Yiwei, WU Fangcai. Prognostic value of nomogram of laboratory inflammation-related indicators in tongue squamous cell carcinoma patients with surgery [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 366-373.
[6]	YANG Chengqing, CUI Yonghui, ZHENG Ziheng. Expression and clinical significance of miR-653-5p in colon cancer patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 261-265.
[7]	QIN Xiyuan, ZHU Ying, LI Weitao, ZHENG Xiaoling, LIANG Yuanqiu. Expression and clinical significance of FoxM1 in epithelial ovarian cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 273-278.
[8]	LIU Ruixue, ZHANG Liwei. Expression and significance of AMPK esophageal squamous cell carcinoma among Kazakhs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 285-291.
[9]	LIU Ying, WANG Rui, GUO Xiao, DONG Lüli, ZHANG Yan, ZHAO Yinhuan, DU Yun. Relationships between DNA ploidy abnormality and EGFR mutation in pleural effusions, and their effects on prognosis of lung adenocarcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 178-182,186.
[10]	WANG Ping, WANG Huayong, WANG Hao, LEI Dajun. Expression of miR-193a and miR-21-5p in serum exosomes from osteosarcoma patients and their clinical values [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 197-201.
[11]	HUANG Lidan, WU Yueming, WANG Yadi, TAN Qi. Relationships between VEGF-A protein expression and EGFR mutation in patients with lung adenocarcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 116-120.
[12]	TAN Jianhua, LAI Yaozhen, TANG Lihua, ZHOU Li. Efficacy and prognostic values of two treatments for advanced epithelial ovarian cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 131-138.
[13]	HU Xueyi, SHEN Feng, WU Lun, SU Caiwu, WEI Jian. SPON2 expression in papillary thyroid carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 9-14.
[14]	XU Hao, HU Bichuan, ZOU Wei, DUAN Yabin. Identification of prognostic factors among patients with stage Ⅲ gastric cancer undergoing radical resection [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 30-36.
[15]	LI Ziyao, ZHANG Haiping, MADINIYET·Niyaz, JULATI·Ainiwaer, ZHANG Liwei, EDRIS·Awut. Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 429-433,438.